To assess whether PKM2 and MAPK8IP2 polymorphisms are associated with ameloblastic carcinoma, the patients with ameloblastic carcinoma were selected and compared to control individuals. This evidence concerns the gene MAPK8IP2 and ameloblastic carcinoma.